<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383460</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS ACLF 01</org_study_id>
    <nct_id>NCT01383460</nct_id>
  </id_info>
  <brief_title>Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure</brief_title>
  <official_title>Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACLF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      50 patients of Acute-on-chronic liver failure (ACLF) will be enrolled and randomized into&#xD;
      G-CSF+EPO or Placebo arms&#xD;
&#xD;
      Treatment protocol To administer G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at&#xD;
      days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with&#xD;
      Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).&#xD;
&#xD;
      Standard medical therapy included as per requirement lactulose, bowel wash, albumin,&#xD;
      terlipressin, antibiotics (if indicated) will be continued and recorded. Pentoxiphylline in&#xD;
      alcoholic hepatitis and Tenofovir in Hep B reactivation Controls: Standard medical therapy&#xD;
      will be given along with placebo in similar prefilled syringes.&#xD;
&#xD;
      Follow up Physical examination will be done daily, after 1 week and at 4 weeks, at 2 months,&#xD;
      at 3 months and at 6 months CBC on alternate day for 1 week, at end of 1 week and then at end&#xD;
      of 4 weeks , at 2 months, at 3 months and at 6 months&#xD;
&#xD;
      KFT on alternate day for 1 week, at end of 1 week and then at end of 4 weeks, at 2 months, at&#xD;
      3 months and at 6 months LFT along with PT/INR on alternate day for 1 week, at end of 1 week&#xD;
      and then at end of 4 weeks, at 2 months, at 3 months and at 6 months AFP at baseline, after 4&#xD;
      weeks, at 3 months and at 6 months Liver regenerative potential efficacy testing at baseline&#xD;
      and after 4 weeks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 patients of ACLF will be enrolled and randomized into G-CSF+EPO or Placebo arms&#xD;
&#xD;
      Baseline investigations:&#xD;
&#xD;
        -  Hematology&#xD;
&#xD;
             -  CBC, Prothrombin time and INR&#xD;
&#xD;
             -  Peripheral smear, Retics&#xD;
&#xD;
        -  Biochemistry&#xD;
&#xD;
             -  Liver function testing, AFP&#xD;
&#xD;
             -  Kidney function test&#xD;
&#xD;
        -  Etiology of acute event:&#xD;
&#xD;
             -  Infectious etiology: IgM anti HAV, IgM anti HEV, IgM anti HBc ( If HBsAg +ve), IgM&#xD;
                anti HDV ( If HBsAg +ve), HEV RNA&#xD;
&#xD;
             -  Non Infectious etiology: Alcohol binging in last 4 weeks, hepatotoxic drugs, ANA&#xD;
                (&gt;1: 80), IgG , surgeries in past 4 weeks, acute variceal bleed within 4 weeks&#xD;
&#xD;
        -  Etiology of underlying chronic liver disease :&#xD;
&#xD;
             -  Infectious etiology: total antiHBc, anti HCV, HCV RNA, HBV DNA&#xD;
&#xD;
             -  Non infectious etiology: Autoimmune markers, copper studies, iron studies, HOMA IR,&#xD;
                FBS Ascitic fluid analysis ( wherever its possible) UGI endoscopy Imaging USG&#xD;
                abdomen with Doppler for spleno-portal axis CECT- Triple phase upper abdomen Liver&#xD;
                regenerative potential efficacy testing (wherever it is possible) Histology ( by&#xD;
                transjugular liver biopsy) Liver Dendritic cells ( CD11c, CD40, CD 54, CD 123, BDCA&#xD;
                2 staining) by flow cytometry CD 34+ cells and CD 133+ cells measurement in hepatic&#xD;
                venous blood, peripheral blood and liver biopsy by flow cytometry Markers of&#xD;
                proliferation like ki- 67, proliferating cell nuclear antigen (PCNA) in hepatic&#xD;
                venous blood and liver biopsy Markers of angiogenesis like VEGF, v WF in hepatic&#xD;
                venous blood Measurement of Hepatic venous pressure gradient ( HVPG)&#xD;
&#xD;
      Treatment protocol To administer G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at&#xD;
      days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with&#xD;
      Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).&#xD;
&#xD;
      Standard medical therapy included as per requirement lactulose, bowel wash, albumin,&#xD;
      terlipressin, antibiotics (if indicated) will be continued and recorded. Pentoxiphylline in&#xD;
      alcoholic hepatitis and Tenofovir in Hep B reactivation Controls: Standard medical therapy&#xD;
      will be given along with placebo in similar prefilled syringes.&#xD;
&#xD;
      Follow up Physical examination will be done daily, after 1 week and at 4 weeks, at 2 months,&#xD;
      at 3 months and at 6 months CBC on alternate day for 1 week, at end of 1 week and then at end&#xD;
      of 4 weeks , at 2 months, at 3 months and at 6 months&#xD;
&#xD;
      KFT on alternate day for 1 week, at end of 1 week and then at end of 4 weeks, at 2 months, at&#xD;
      3 months and at 6 months LFT along with PT/INR on alternate day for 1 week, at end of 1 week&#xD;
      and then at end of 4 weeks, at 2 months, at 3 months and at 6 months AFP at baseline, after 4&#xD;
      weeks, at 3 months and at 6 months Liver regenerative potential efficacy testing at baseline&#xD;
      and after 4 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant free survival at 3 months.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant free survival at 6 months, histo-pathological evidence of hepatic regeneration and mobilization of CD34/stem cells, improvement in severity assessment indices</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Acute on Chronic Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>G-CSF+EPO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)</intervention_name>
    <description>G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).</description>
    <arm_group_label>G-CSF+EPO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All consecutive patients with acute hepatic insult manifesting as jaundice (Sr. Bil. ≥ 5&#xD;
        mg/dL) and coagulopathy (INR≥1.5), complicated within 4 weeks by ascites and/or&#xD;
        encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;12 or &gt; 75 years&#xD;
&#xD;
          -  Autoimmune disorders&#xD;
&#xD;
          -  HCC&#xD;
&#xD;
          -  Sepsis ( Any culture positive: blood, urine, any other obvious source of infection:&#xD;
             UTI, SBP)&#xD;
&#xD;
          -  Multi organ failure&#xD;
&#xD;
          -  Grade 4 HE&#xD;
&#xD;
          -  HIV seropositivity / pregnancy&#xD;
&#xD;
          -  Essential Hypertension&#xD;
&#xD;
          -  Patients being taken up for transplant&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiv Kumar Sarin, MD, DM</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 26, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>December 4, 2016</last_update_submitted>
  <last_update_submitted_qc>December 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute-on-chronic liver failure</keyword>
  <keyword>ACLF</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>acute hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

